Michael Chez to Humans
This is a "connection" page, showing publications Michael Chez has written about Humans.
Connection Strength
0.740
-
Exploring proposed recommendations for immediate-use seizure medication: Treating both cluster and prolonged seizures with diazepam nasal spray. Epilepsia Open. 2025 Aug; 10(4):999-1008.
Score: 0.095
-
A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism. J Autism Dev Disord. 2020 May; 50(5):1532-1538.
Score: 0.067
-
Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism. Stem Cells Transl Med. 2018 04; 7(4):333-341.
Score: 0.058
-
Immune therapy in autism: historical experience and future directions with immunomodulatory therapy. Neurotherapeutics. 2010 Jul; 7(3):293-301.
Score: 0.034
-
Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment. Paediatr Drugs. 2009; 11(6):397-406.
Score: 0.031
-
Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol. 2007 Jun; 36(6):361-5.
Score: 0.027
-
Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007 May; 22(5):574-9.
Score: 0.027
-
Addressing Barriers to Transitioning Pediatric Patients With Epilepsy to Adult Health Care in the United States: A Narrative Review. Neurol Clin Pract. 2026 Jun; 16(3):e200616.
Score: 0.025
-
Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy Behav. 2006 Feb; 8(1):267-71.
Score: 0.025
-
Effectiveness and safety of perampanel by concomitant antiseizure medications: Insights from the real-world PERMIT Extension study. Epilepsy Behav. 2025 Oct; 171:110651.
Score: 0.024
-
Immunizations, immunology, and autism. Semin Pediatr Neurol. 2004 Sep; 11(3):214-7.
Score: 0.023
-
Neurologic treatment strategies in autism: an overview of medical intervention strategies. Semin Pediatr Neurol. 2004 Sep; 11(3):229-35.
Score: 0.023
-
Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher-level emergency: Consensus recommendations of an expert working group. Epileptic Disord. 2024 Aug; 26(4):484-497.
Score: 0.022
-
Frequency of EEG abnormalities in age-matched siblings of autistic children with abnormal sleep EEG patterns. Epilepsy Behav. 2004 Apr; 5(2):159-62.
Score: 0.022
-
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004 Mar; 19(3):165-9.
Score: 0.022
-
Outcome measures for clinical drug trials in autism. CNS Spectr. 2004 Jan; 9(1):36-47.
Score: 0.022
-
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program. Epilepsia. 2023 08; 64(8):e156-e163.
Score: 0.021
-
Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion. Seizure. 2023 Aug; 110:42-57.
Score: 0.021
-
Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002 Nov; 17(11):833-7.
Score: 0.020
-
PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy. Epilepsia Open. 2022 06; 7(2):293-305.
Score: 0.019
-
Overcoming presynaptic effects of VAMP2 mutations with 4-aminopyridine treatment. Hum Mutat. 2020 11; 41(11):1999-2011.
Score: 0.017
-
Secretin and autism: a two-part clinical investigation. J Autism Dev Disord. 2000 Apr; 30(2):87-94.
Score: 0.017
-
AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat Commun. 2019 07 12; 10(1):3094.
Score: 0.016
-
Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid. J Child Neurol. 1999 Apr; 14(4):239-42.
Score: 0.016
-
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019 08; 154:13-20.
Score: 0.016
-
Ibuprofen-induced meningitis: detection of intrathecal IgG synthesis and immune complexes. Neurology. 1989 Dec; 39(12):1578-80.
Score: 0.008
-
Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry. 2006 Feb 15; 59(4):354-63.
Score: 0.006
-
Relief of psychiatric symptoms in a patient with Crohn's disease after metronidazole therapy. Clin Infect Dis. 2000 Jan; 30(1):213-4.
Score: 0.004
-
Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders. Pediatrics. 1999 Sep; 104(3 Pt 1):405-18.
Score: 0.004
-
Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr. 1999 May; 134(5):607-13.
Score: 0.004
-
Antibodies to ACTH in opsoclonus-myoclonus. Neuropediatrics. 1993 Jun; 24(3):131-3.
Score: 0.003
-
Acute septic arthritis due to Acremonium. J Rheumatol. 1988 Apr; 15(4):714-5.
Score: 0.002